• TC BioPharm, Trinity College Dublin Pair to Develop Cancer-fighting Cell Therapy
  • Immune Checkpoint Inhibitors Safe, Effective in HIV-positive Patients with Advanced Cancer, Research Reveals
  • Subtypes of Immune Cells in Tumor Environment Can Predict Follicular Lymphoma Response to Therapy
  • Phase 3 Keytruda Trial Fails Primary Objectives in Liver Cancer Patients Who Received Prior Nexavar
  • FDA Places Partial Hold on Xencor’s Phase 1 Trial of XmAb14045 Immunotherapy for Blood Cancers
  • FDA Grants Priority Review to Keytruda for Advanced Small Cell Lung Cancer
  • Specific Gene Mutations Predict Success of Immunotherapy in Glioblastoma Patients, Study Reports
  • FDA Approves Keytruda for Melanoma Patients After Tumor Resection
  • First Mesothelioma Patient Dosed in Phase 1 Trial of Curis’ CA-170
  • Keytruda Better Than Chemotherapy for Untreated Advanced Merkel Cell Carcinomas, Phase 2 Trial Suggests
  • FDA Grants Priority Review to Keytruda-Inlyta Combo for Untreated, Advanced Kidney Cancer Patients
  • European Panel Favors Approval of Keytruda-Chemo Combo as First-line Therapy for NSCLC